CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
CRA Competition's response to EU Draft Merger Guidelines: An economic perspective on the emerging framework
Our European Competition team has contributed to the economic assessment in nearly a third of distinct merger decisions cited in the draft, (46 out of 164)...